• Targeted platform. An E102_I103del mutation in MAP2K1 was identified in one BRAF wild-type case and confirmed by Sanger sequencing. Analysis of 32 additional cases using BRAF V600E allele-specific PCR and Sanger sequencing of MAP2K1 exons 2 and 3 revealed somatic, mutually exclusive BRAF and MAP2K1 mutations in a total of 18/40 (45.0%) and 11/40 (27.5%) cases, respectively. This is the first report of MAP2K1 mutations in LCH which occur in 50% of BRAF wild-type cases. The mutually exclusive nature of MAP2K1 and BRAF mutations implicates a critical role of oncogenic MAPK signaling in LCH. This finding may also have implications for the use of BRAF and MEK inhibitor therapy.
Introduction
Langerhans cell histiocytosis (LCH) is characterized by a clonal proliferation of specialized cells with characteristics resembling antigen presenting cells that reside in the skin and mucosa. 1 The disease manifests a broad clinical spectrum ranging from focal and self-limited disease to aggressive multisystem disease with 20% mortality 2 . BRAF V600E mutations have been identified in 38% to 57% of LCH cases. 3, 4 This mutation results in constitutive activation of the mitogen-activated protein kinase (MAPK)
pathway. Since this discovery, patients with BRAF V600E mutated LCH have been successfully treated with BRAF inhibitors. 5 Badalian-Very et al. 3 noted that the intensity of Langerhans cell immunohistochemical staining for phosphorylated downstream mediators of the MAPK pathway did not vary with BRAF mutation status. This finding suggests another mechanism of MAPK pathway activation in BRAF wild-type cases. We sought to identify mutations that may contribute to the pathogenesis of LCH in cases without BRAF V600E mutations.
Methods
We studied cases of Langerhans cell histiocytosis within the archives of the Department of Pathology at the University of Michigan with institutional review board approval (HUM00023256) and in accordance with the Declaration of Helsinki. DNA was extracted from available non-decalcified, formalin-fixed paraffin-embedded samples in which at least 30% neoplastic nuclei could be isolated using the Pinpoint Slide DNA Isolation System (Zymo Research). To discover genetic mechanisms that might explain ERK1 activation in the absence of BRAF V600E, we initially screened 8 LCH cases using both BRAF V600E allele-specific PCR and the Ion AmpliSeq Comprehensive Cancer Panel. Allele-specific PCR was performed as previously described by Brown et al. Emulsification PCR was performed using the One Touch DL instrument and template-positive Ion Sphere particles were enriched using the OneTouch ES instrument according to the manufacturer's instructions.
Sequencing was performed on a 318 chip on the Ion Torrent PGM following the recommended protocol.
Reads were aligned to hg19 and variants were called using the Torrent Suite 4.0.2.
Upon identification of a MAP2K1 mutation within exon 3 in one of 8 cases using the Ion AmpliSeq
Comprehensive Cancer panel, we evaluated all eight cases using bidirectional Sanger sequencing of MAP2K1 exons 2 and 3. An additional 32 cases of LCH were then evaluated using BRAF V600E allelespecific PCR and MAP2K1 exon 2 and 3 bidirectional Sanger sequencing. DNA was sequenced using the BigDye Terminator V1.1 sequencing kit (Applied Biosystems) and the 3130xl DNA Analyzer (Applied Biosystems). Primers are listed in supplemental Table 1 . Sanger sequencing of exon 15 of the BRAF gene was performed for one case with a BRAF insertion mutation as described by Hookim et al. 
Results and Discussion
Similar to previous reports, a BRAF V600E mutation was detected in 3 of the initially screened 8 cases.
An E102_I103del mutation in MAP2K1 was identified in one BRAF wild-type case using the Ion 9 and recently in BRAF V600E-negative hairy cell leukemia. 10 The MAP2K1 mutations identified in this study were located in the negative regulatory region encoded by exon 2 and the catalytic core encoded by exon 3 ( Figure 1B ; Table 1 ). 11, 12 Similar mutations affecting these sites have previously been demonstrated to result in constitutive activation of the MAPK pathway in non-hematologic neoplasms. [13] [14] [15] [16] By comparison with the predominance of missense mutations observed in other neoplasms, the majority of MAP2K1 mutations in LCH were in-frame deletions. Six in-frame deletions involved exon 3 including residues E102 and I103 ( Figure 1C ). Two cases of mutations involving this site have been described in melanoma and lung adenocarcinoma. Deletions involving this region have been reported to have 60-fold increased MEK1 enzymatic activity.
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Five missense mutations were also identified -R47Q, R49C, A106T, C121S and G128V. The C121S mutation has been shown to increase kinase activity and promote melanoma cell proliferation.
5
Of note, two of our cases demonstrated two separate missense mutations at similar allele frequencies -one case with C121S and G128V ( Figure 1D ) and one case with R49C and A106T. The former patient was diagnosed at birth, suffered aggressive multisystem disease refractory to several therapies, and died at 19 months of age (supplemental Table 2 ).
Because MEK1 is downstream of BRAF within the MAPK pathway, LCH patients with MAP2K1 mutations would not be expected to benefit from BRAF inhibitor therapy. Accordingly, MAP2K1
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From mutations have been demonstrated to confer resistance to BRAF inhibitor therapy in other neoplasms. 18 Several small molecule inhibitors targeting MEK are FDA-approved or in clinical trials for the treatment of neoplasms with activating MAPK pathway mutations, principally BRAF mutated melanoma with and without MAP2K1 mutations. [19] [20] [21] [22] However, at least one mutation identified in this study -C121S -has been shown to confer resistance to both BRAF inhibitors and current MEK inhibitors.
Nevertheless, MEK1 and its downstream kinase ERK remain attractive targets for therapy in LCH.
In conclusion, this is the first report of somatic MAP2K1 mutations in LCH which occur in 50% of BRAF wild-type cases. The mutually exclusive nature of MAP2K1 and BRAF mutations suggests that each of these mutations may function as an initiating mutation driving proliferation of Langerhans cells through a common pathway. This finding may also have implications for the use of BRAF and MEK inhibitor therapy.
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